Therefore, we performed a meta-analysis to ascertain: i) whether OPN is a useful tumor biomarker in ovarian cancer when used alone; ii) whether OPN can improve the accuracy of CA125 in diagnosis of ovarian cancer; and iii) whether and how future studies are needed to verify the diagnostic value of osteopontin for ovarian cancer. Here, MUC16 is linked to ovarian carcinoma.